Open an account

Legend Biotech

LEGN · NASDAQ

$19.01+$0.36 (+1.93%)TodayMarket closed ·
Prev close $18.65

About LEGN

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees
2,900
Headquarters
Somerset, New Jersey
Listed
Jun 4, 2020
Sector
Health Care
Industry
Biotechnology
Website
investors.legendbiotech.com

LEGN key statistics

Market cap
3.61B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.19M
Volume
1.14M
Open price
$18.83
High today
$19.15
Low today
$18.60
52 Week high
$37.50
52 Week low
$16.24

Legend Biotech (LEGN) at a glance

As of Oct 20, 2026, Legend Biotech (LEGN) shares are priced at $19.01, giving the company a market cap of 3.61B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $18.60 and $19.15. The current price is 2.2% above the day's low and 0.7% below its high.

Volume so far is 1.14M shares, below the average of 2.19M shares a day.

Over the past year Legend Biotech has ranged from $16.24 to $37.50, and now sits 13% of the way up that range.

Legend Biotech met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported $0.18 per share against an estimate of $0.0764.

The average analyst price target is $51.13, 169.0% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

60%of 10 analyst ratings say Buy
  • Buy60.0%
  • Hold40.0%
  • Sell0.0%
Price target · 19 analystsAvg $51.13
Low
$24.24
Now
$19.01
High
$77.70

LEGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 141.3% on average.

  1. Q3 FY24: reported -$0.68 per share against an estimate of -$0.4153
  2. Q4 FY24: reported $0.15 per share against an estimate of -$0.3188
  3. Q1 FY25: reported -$0.54 per share against an estimate of -$0.2275
  4. Q2 FY25: reported -$0.68 per share against an estimate of -$0.1459
  5. Q3 FY25: reported -$0.22 per share against an estimate of -$0.0861
  6. Q4 FY25: reported -$0.16 per share against an estimate of -$0.1107
  7. Q1 FY26: reported -$0.30 per share against an estimate of -$0.0215
  8. Q2 FY26: reported $0.18 per share against an estimate of $0.0764

LEGN news

  • Vandana Singh

    Why Is Legend Biotech Stock Falling Thursday?

  • 10 Health Care Stocks Whale Activity In Today's Session

  • An Overview of Legend Biotech's Earnings

  • What to Expect from Legend Biotech's Earnings

  • Press releaseGlobe Newswire

    Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

  • 'Legend Biotech Is Said to Explore Second Listing Outside of US'- Bloomberg

  • Press releaseGlobe Newswire

    Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results

  • Press releaseGlobe Newswire

    Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

Similar companies

Companies in the same industry as Legend Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.